LOS ANGELES (AP) — The world's biggest social media companies face several landmark trials this year that seek to hold them responsible for harms to children who use their platforms.
Methanex (NASDAQ:MEOH – Get Free Report) (TSE:MX) was downgraded by investment analysts at CIBC World Markets from an “outperform” rating to a “neutral” rating in a research report issued on Saturday,BayStreet.CA reports. They presently have a $52.00 price objective on the specialty chemicals company’s stock, up from their previous price objective of $46.00. CIBC World [...]
ABU DHABI – The UAE Fatwa Council has officially announced the amounts for Fitrana (Zakat al-Fitr) and Fidyah for Ramadan 2026 after conducting a field price study in collaboration with the Ministry of Economy and Tourism. For Fitrana, the amount has been set at 2.5 kilograms of rice or 25 AED per person. For those [...]The post Fitrana, Fidyah amounts announced for Ramadan 2026 appeared first on Daily Pakistan English News.
The latest report titled "Shop Primer Market" Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033. offering a comprehensive and in-depth analysis of the industry. The report provides key insights into current market trends, growth drivers, challenges, and opportunities shaping the
Greek exports continued their advance last year in the face of adversity in global trade.
STMicroelectronics expands strategic engagement with Amazon Web Services to enable new high performance compute infrastructure for cloud and AI data centers Stocks master_of_puppetsMon 09/02/2026 - 07:00 NL0000226223 NL0000226223 09/02/2026 - 07:00 Paris Milan STMicroelectronics expands strategic engagement with Amazon Web Services to enable new high performance compute infrastructure for cloud and AI data centers Alliances and agreements 1001163630-en GlobeNewswire STMicroelectronics International NV Euronext Published 10102010 Semiconductors XPAR MTAA Language English PR N°C3385C STMicroelectronics expands strategic engagement with Amazon Web Services to enable new high performance compute infrastructure for cloud and AI data centers Geneva, February 9, 2026 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, today announced an expanded strategic collaboration with Amazon Web Services (AWS) through a multi-year, multi-billion USD commercial engagement serving several product categories. The collaboration establishes ST as a strategic supplier of advanced semiconductor technologies and products that AWS integrates into its compute infrastructure, enabling AWS to provide customers with new high performance compute instances, reduced operational costs, and the ability to scale compute-intensive workloads more effectively. Commercial AgreementThis engagement covers a broad range of semiconductor solutions leveraging ST's portfolio of proprietary technologies. ST will supply specialized capabilities across high-bandwidth connectivity, including high-performance mixed-signal processing, advanced microcontrollers for intelligent infrastructure management, as well as analog and power ICs that deliver the energy efficiency required for hyperscale data center operations. The collaboration will help customers reduce total cost of ownership and bring products to market faster. ST's specialized technologies help AWS address the increasing demands for compute performance, efficiency, and data throughput required to support growing AI and cloud workloads. Jean-Marc Chery, ST President & CEO, commented: "This strategic engagement establishes ST as an important supplier to AWS and validates the strength of our innovation, proprietary technology portfolio, and proven manufacturing-at-scale capabilities. Our advanced semiconductor solutions will directly power AWS's next-generation infrastructure, enabling their customers to push the boundaries of AI, high-performance computing, and digital connectivity. This collaboration positions us ideally for further scale-up across multiple market segments, from data center infrastructure to AI connectivity, positioning ST at the center of the AI revolution." As part of this expanded relationship, ST will work with AWS to optimize electronic design automation (EDA) workloads in the cloud. AWS's scalable compute power enables silicon design acceleration, parallelizes design tasks, and gives engineering teams the flexibility to handle dynamic compute demands and speed products to market. ST has issued warrants to AWS for the acquisition of up to 24.8 million ordinary shares of ST. The warrants will vest in tranches over the term of the agreement, with vesting substantially tied to payments for ST products and services purchased by AWS and its affiliates. AWS may exercise the warrants in one or more transactions over a seven-year period from the issue date at an initial exercise price of $28.38. Forward-looking Information Some of the statements contained in this release that are not historical facts are statements of future expectations and other forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933 or Section 21E of the Securities Exchange Act of 1934, each as amended) that are based on management’s current views and assumptions, and are conditioned upon and also involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated by such statements due to, among other factors: changes in global trade policies, including the adoption and expansion of tariffs and trade barriers, that could affect the macro-economic environment and directly or indirectly adversely impact the demand for our products;uncertain macro-economic and industry trends (such as inflation and fluctuations in supply chains), which may impact production capacity and end-market demand for our products;customer demand that differs from projections which may require us to undertake transformation measures that may not be successful in realizing the expected benefits in full or at all;the ability to design, manufacture and sell innovative products in a rapidly changing technological environment;changes in economic, social, public health, labor, political, or infrastructure conditions in the locations where we, our customers, or our suppliers operate, including as a result of macro-economic or regional events, geopolitical and military conflicts, social unrest, labor actions, or terrorist activities;unanticipated events or circumstances, which may impact our ability to execute our plans and/or meet the objectives of our R&D and manufacturing programs, which benefit from public funding;financial difficulties with any of our major distributors or significant curtailment of purchases by key customers;the loading, product mix, and manufacturing performance of our production facilities and/or our required volume to fulfill capacity reserved with suppliers or third-party manufacturing providers;availability and costs of equipment, raw materials, utilities, third-party manufacturing services and technology, or other supplies required by our operations (including increasing costs resulting from inflation); the functionalities and performance of our IT systems, which are subject to cybersecurity threats and which support our critical operational activities including manufacturing, finance and sales, and any breaches of our IT systems or those of our customers, suppliers, partners and providers of third-party licensed technology;theft, loss, or misuse of personal data about our employees, customers, or other third parties, and breaches of data privacy legislation; the impact of IP claims by our competitors or other third parties, and our ability to obtain required licenses on reasonable terms and conditions; changes in our overall tax position as a result of changes in tax rules, new or revised legislation, the outcome of tax audits or changes in international tax treaties which may impact our results of operations as well as our ability to accurately estimate tax credits, benefits, deductions and provisions and to realize deferred tax assets; variations in the foreign exchange markets and, more particularly, the U.S. dollar exchange rate as compared to the Euro and the other major currencies we use for our operations; the outcome of ongoing litigation as well as the impact of any new litigation to which we may become a defendant; product liability or warranty claims, claims based on epidemic or delivery failure, or other claims relating to our products, or recalls by our customers for products containing our parts; natural events such as severe weather, earthquakes, tsunamis, volcano eruptions or other acts of nature, the effects of climate change, health risks and epidemics or pandemics in locations where we, our customers or our suppliers operate; increased regulation and initiatives in our industry, including those concerning climate change and sustainability matters and our goal to become carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027; epidemics or pandemics, which may negatively impact the global economy in a significant manner for an extended period of time, and could also materially adversely affect our business and operating results;industry changes resulting from vertical and horizontal consolidation among our suppliers, competitors, and customers;the ability to successfully ramp up new programs that could be impacted by factors beyond our control, including the availability of critical third-party components and performance of subcontractors in line with our expectations; and individual customer use of certain products, which may differ from the anticipated uses of such products and result in differences in performance, including energy consumption, may lead to a failure to achieve our disclosed emission-reduction goals, adverse legal action or additional research costs. Such forward-looking statements are subject to various risks and uncertainties, which may cause actual results and performance of our business to differ materially and adversely from the forward-looking statements. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as “believes”, “expects”, “may”, “are expected to”, “should”, “would be”, “seeks” or “anticipates” or similar expressions or the negative thereof or other variations thereof or comparable terminology, or by discussions of strategy, plans or intentions. Some of these risk factors are set forth and are discussed in more detail in “Item 3. Key Information — Risk Factors” included in our Annual Report on Form 20-F for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (“SEC”) on February 27, 2025. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed or expected. We do not intend, and do not assume any obligation, to update any industry information or forward-looking statements set forth in this release to reflect subsequent events or circumstances. Unfavorable changes in the above or other factors listed under “Item 3. Key Information — Risk Factors” from time to time in our SEC filings, could have a material adverse effect on our business and/or financial condition. About STMicroelectronics At ST, we are 48,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at https://www.globenewswire.com/Tracker?data=zTDYyJFoFRN3VJx1cTOouFzIlGuG...; rel="nofollow" target="_blank">.www.st.com.; For further information, please contact: INVESTOR RELATIONSJérôme RamelEVP Corporate Development & Integrated External Communication Tel: +41 22 929 59 20 jerome.ramel@st.com MEDIA RELATIONSAlexis BretonGroup VP Corporate External CommunicationsTel: +33 6 59 16 79 08https://www.globenewswire.com/Tracker?data=JhxwpbzEVR_dhVpiLEz_RTj6dwiV...; rel="nofollow" target="_blank">alexis.breton@st.com Attachment C3385C">https://ml-eu.globenewswire.com/Resource/Download/7f97002b-f3d9-44e7-b5... - ST expands strategic engagement with AWS _09feb2026 https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE2MzYzMCM0MDIzMjk0Nj...; /> https://ml-eu.globenewswire.com/media/MGI4MzI2YmMtYmUyZi00N2NmLTg3N2UtZ...; referrerpolicy="no-referrer-when-downgrade" /> STMICROELECTRONICS STMicroelectronics N.V. 058208 NL0000226223-XPAR NL0000226223-MTAA STMPA STMMI
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Stocks master_of_puppetsMon 09/02/2026 - 07:00 FR0000120578 FR0000120578 FR0000120578 Rilza English 09/02/2026 - 07:00 Paris Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Other subject 1001163554-en GlobeNewswire Sanofi Winthrop Industrie Euronext Published 20103015 Pharmaceuticals XPAR BGEM ETLX Language English Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi for warm autoimmune hemolytic anemia to be designated Breakthrough Therapy by the FDA Rilzabrutinib helps address complex immune-system dysregulation through multi-immune modulationRilzabrutinib holds global regulatory designations across multiple rare diseases, underscoring its broad therapeutic potential Paris, February 9, 2026. The US Food and Drug Administration (FDA) has granted a designation as breakthrough therapy to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA), a rare autoimmune disorder marked by the destruction of red blood cells. The Japanese Ministry of Health, Labour and Welfare has also provided rilzabrutinib an orphan designation for the same condition. Both designations are based on clinical data from the ongoing LUMINA 2 phase 2b study (clinical study identifier: https://clinicaltrials.gov/study/NCT05002777" rel="nofollow" target="_blank">NCT05002777) assessing the efficacy and safety of rilzabrutinib for patients with wAIHA. In addition, the new LUMINA 3 phase 3 study (clinical study identifier: https://clinicaltrials.gov/study/NCT07086976" rel="nofollow" target="_blank">NCT07086976), is assessing rilzabrutinib compared with placebo in patients with wAIHA. There is currently no approved treatment that specifically targets the underlying cause of this rare autoimmune condition, which can lead to anemia, fatigue, and serious organ damage. An FDA breakthrough therapy designation is designed to expedite the development and review of medicines in the US intended to treat serious or life-threatening conditions and where preliminary clinical evidence indicates the therapy may demonstrate substantial improvement over available treatment options. Orphan designation in Japan is granted to medicines intended to address rare diseases with high unmet medical need. “These recognitions highlight the critical unmet need that persists for people living with wAIHA,” said Karin Knobe, Global Head of Development, Rare Diseases. “Furthermore, receiving such designations reinforces our commitment to advancing innovative medicines for rare diseases that currently have limited or no approved treatment options.” Rilzabrutinib is approved in the US, the EU, and the United Arab Emirates (UAE) under the brand name Wayrilz for the treatment of adults with immune thrombocytopenia (ITP) and is currently under regulatory review for ITP in Japan. Other than the approved ITP indications in the US, EU, and UAE, these uses of rilzabrutinib are investigational and have not been evaluated by any regulatory authority. The FDA previously granted rilzabrutinib orphan drug designation for autoimmune hemolytic anemia, as well as two other rare diseases, IgG4-related disease (IgG4-RD) and sickle cell disease (SCD). Rilzabrutinib also received FDA fast track designation for ITP and IgG4-RD and EU orphan designation in ITP, autoimmune hemolytic anemia, and IgG4-RD. About wAIHAwAIHA is a rare, potentially life-threatening, autoimmune disorder rooted in complex immune system dysregulation. It represents more than half of autoimmune hemolytic anemia cases. In wAIHA, autoantibodies lead to the premature destruction of the body’s own red blood cells (hemolysis), sometimes faster than the bone marrow can replace them. In the US and EU, autoimmune hemolytic anemia is estimated to affect four to 24 people out of 100,000, while in Japan it is rarer, affecting three to 10 people per million. People living with wAIHA may experience debilitating fatigue, dizziness, palpitations, and shortness of breath, and may face complications such as thromboembolism. About rilzabrutinibRilzabrutinib, Wayrilz where approved, is a novel, oral, reversible covalent BTK inhibitor that has the potential to be an effective new medicine for several rare immune-mediated or inflammatory diseases by working to restore immune balance via multi-immune modulation. BTK, expressed in B cells, macrophages, and other innate immune cells, plays a critical role in multiple immune-mediated disease processes and inflammatory pathways. With the application of the TAILORED COVALENCY® technology, rilzabrutinib can selectively inhibit the BTK target. Wayrilz is now approved for the treatment of immune thrombocytopenia (ITP) in the US, the EU, and the UAE. Regulatory review for use in ITP is currently ongoing in Japan. In addition to ITP and wAIHA, rilzabrutinib is being studied across a variety of rare diseases, including IgG4-RD and SCD. These additional indications are currently under investigation and have not been approved by regulatoryauthorities. About SanofiSanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | mailto:sandrine.guendoul@sanofi.com" rel="nofollow" target="_blank">sandrine.guendoul@sanofi.comEvan Berland | +1 215 432 0234 | mailto:evan.berland@sanofi.com" rel="nofollow" target="_blank">evan.berland@sanofi.com Timothy Gilbert | +1 516 521 2929 | mailto:timothy.gilbert@sanofi.com" rel="nofollow" target="_blank">timothy.gilbert@sanofi.comLéo Le Bourhis | +33 6 75 06 43 81 | mailto:leo.lebourhis@sanofi.com" rel="nofollow" target="_blank">leo.lebourhis@sanofi.com Victor Rouault | +33 6 70 93 71 40 | mailto:victor.rouault@sanofi.com" rel="nofollow" target="_blank">victor.rouault@sanofi.comLéa Ubaldi | +33 6 30 19 66 46 | mailto:lea.ubaldi@sanofi.com" rel="nofollow" target="_blank">lea.ubaldi@sanofi.comEkaterina Pesheva | +1 410 926 6780 | mailto:ekaterina.pesheva@sanofi.com" rel="nofollow" target="_blank">ekaterina.pesheva@sanofi.com Investor RelationsThomas Kudsk Larsen | + 44 7545 513 693 | mailto:thomas.larsen@sanofi.com" rel="nofollow" target="_blank">thomas.larsen@sanofi.comAlizé Kaisserian | + 33 6 47 04 12 11 | mailto:alize.kaisserian@sanofi.com" rel="nofollow" target="_blank">alize.kaisserian@sanofi.comKeita Browne | + 1 781 249 1766 | mailto:keita.browne@sanofi.com" rel="nofollow" target="_blank">keita.browne@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | mailto:nathalie.pham@sanofi.com" rel="nofollow" target="_blank">nathalie.pham@sanofi.comNina Goworek | +1 908 569 7086 mailto:nina.goworek@sanofi.com" rel="nofollow" target="_blank">nina.goworek@sanofi.comThibaud Châtelet | + 33 6 80 80 89 90 | mailto:thibaud.chatelet@sanofi.com" rel="nofollow" target="_blank">thibaud.chatelet@sanofi.comYun Li | +33 6 84 00 90 72 | mailto:yun.li3@sanofi.com" rel="nofollow" target="_blank">yun.li3@sanofi.comSanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Rilza">https://ml-eu.globenewswire.com/Resource/Download/073adbac-0c70-44c8-8a... English https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE2MzU1NCM0MDIzMjkxOD...; /> https://ml-eu.globenewswire.com/media/OGZhYzZmOTItZTQyZi00ODg1LWIyODctO...; referrerpolicy="no-referrer-when-downgrade" /> SANOFI SANOFI 078526 FR0000120578-XPAR FR0000120578-BGEM FR0000120578-ETLX SAN 1SAN 4SAN
From the moment I first logged into Moltbook, dubbed “the Reddit for AI agents”, I felt like a...The post Moltbook and the ethics of invisible AI communities: A conversation with Remond Odiaga first appeared on Technext.
There's a new trio of signs that suggest capital is flowing to the chain via a couple of important vehicles.
WISeKey’s WISe.Art and GMA Once Again Revolutionize the Future of Art and Technology in an Extraordinary Event in Venice
If the service continues it is likely to cost Cornish taxpayers between £14 million and £16 million over the next four years
PINELAND — Pineland will never be another Dallas.